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ABSTRACT
Production of sphingosine-1-phosphate (S1P) is linked to 17b-estradiol (E2) activity in many estrogen-responsive cells; in bone
development, the role of S1P is unclear. We studied effects of S1P on proliferation and differentiation of human osteoblasts (hOB). Ten nM
E2, 1mMS1P, or 1mMof the S1P receptor 1 (S1PR1) agonist SEW2871 increased hOB proliferation at 24 hours. S1PR 1, 2, and 3mRNAs are
expressed by hOB but not S1PR4 or S1PR5. Expression of S1PR2 was increased at 7 and 14 days of differentiation, in correspondence with
osteoblast-related mRNAs. Expression of S1PR1 was increased by E2 or S1P in proliferating hOB, whereas S1PR2 mRNA was unaffected in
proliferating cells; S1PR3was not affected by E2 or S1P. Inhibiting sphingosine kinase (SPHK) activitywith sphingosine kinase inhibitor (Ski)
greatly reduced theE2proliferativeeffect. BothE2andS1P increasedSPHKmRNAat24hours inhOB. S1Ppromotedosteoblastproliferation
via activatingMAPkinaseactivity. Either E2or S1P increasedS1Psynthesis in afluorescent S1Passay. Interactionof E2andS1P signalingwas
indicated by upregulation of E2 receptor mRNA after S1P treatment. E2 and S1P also promoted alkaline phosphatase expression. During
osteoblast differentiation, S1P increasedbone-specificmRNAs, similarly to the effects of E2. However, E2 andS1P showeddifferences in the
activation of some osteoblast pathways. Pathway analysis by gene expression arrays was consistent with regulation of pathways of
osteoblast differentiation; collagen and cell adhesion proteins centered on Rho/Rac small GTPase signaling and Map kinase or signal
transducer and activator of transcription (Stat) intermediates. Transcriptional activation also included significant increases in superoxide
dismutase 1 and 2 transcription by either S1P or E2.Wedemonstrate that the SPHK system is a co-mediator for osteoblast proliferation and
differentiation, which is mainly, but not entirely, complementary to E2, whose effects are mediated by S1PR1 and S1PR2. © 2018 The
Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
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Introduction
Balanced bone formation by osteoblasts and bone resorptionby osteoclasts is required to maintain bone mass. Osteo-
blasts are regulated by a number of cytokines and growth
factors, including the lipid-derived secondary extracellular
signaling molecule sphingosine-1-phosphate (S1P). In bone,
S1P is produced both by osteoblasts(1) and osteoclasts.(2)
Circulating S1P in humans is associated with a negative effect
on bone mass,(3) although S1P in osteoblasts promotes growth
and survival.(4) Estrogen modulates S1P production in cells
including astroglia, breast, and endothelium.(5–7) In bone,
estrogen is essential for skeletal development and maintenance
with a mixture of direct and indirect effects on growth and on
the balance of bone formation and resorption.(8) The relation of
estrogen and S1P signaling in bone is poorly studied.
S1P is synthesized from sphingosine by sphingosine kinases
(SPHK), and it acts by G-protein coupled receptors (S1PRs). S1P
modifies proliferation, differentiation, migration, survival, and
calcium homeostasis in a variety of cells by coupling receptor of
activation to a variety of downstream activators including Map
kinases and transcription factors.(9) S1P is irreversibly degraded
by S1P lyase to palmitaldehyde, and its phosphorylation is
reversed by phosphatases.(10) Several plasma membrane
sphingosine-1 phosphate receptors(11) mediate pathophysio-
logical effects of S1P; because of specific links of individual
receptors to effects, receptor-specific inhibitors are potential
therapeutic agents.(12)
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We investigated the effect of estradiol and S1P in human
osteoblast precursors, including on osteoblast differentiation,
osteoblast production of S1P, and S1P signaling in osteoblasts.
Effects of S1P on osteoblast proliferation and differentiation
were examined. Molecular Pathway analysis using Affymetrix
arrays to study whole-genome mRNA expression showed that
S1P and estradiol have many similar effects on osteoblast
proliferation and differentiation, although differences were




17-b-Estradiol (estradiol) was from Sigma-Aldrich (St. Louis, MO,
USA). D-erythro-sphingosine-1-phosphate (S1P) was from Avanti
Polar Lipids (Alabaster, AL, USA). The S1P receptor-1 (S1PR1)
agonist SEW2871 was from Tocris (Bristol, UK). The sphingosine
kinase inhibitor 5-(2-Naphthalenyl)-1H-pyrazole-3-carboxylic
acid 2-[(2-hydroxy-1-naphthalenyl) methylene] hydrazide (SKi)
was from EMD Chemical (Gibbstown, NJ, USA).
Cells
Normal human osteoblasts, CC-2538, and normal human bone
marrow-derived mesenchymal stem cells, PT-2501 (Lonza,
Allendale, NJ, USA), were used, grown in medium containing
fetal bovine serum and gentamicin and amphotericin-B. For
differentiation, 10mM glycerol-2-phosphate, 50mg/mL ascorbic
acid (Lonza), 2mM CaCl2, and 10 nM 1,25-dihydroxy vitamin D3
were added. Charcoal-stripped fetal bovine serum was used to
eliminate endogenous lipids. Cells were grown at 37°C with 5%
CO2. At 80% confluence, cells were detached with 0.05% trypsin
in 0.02% EDTA. All experiments were performed after the third
passage. Media were replaced at 2- to 3-day intervals.
Cell proliferation
Cells were plated at 9000/cm2. Proliferation was estimated by
colorimetric MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenylte-
trazolium bromide) assay. The reaction product, a blue formazan
derivative, was measured photometrically after MTT, 0.5mg/mL,
was added to each well and incubated at 37°C for 4 hours.
Dimethylsulfoxide was added to each well to solubilize the
formazan crystals. Microtiter plates were placed on a shaker for 5
minutes, and absorbance was measured at 570 nm. Regarding
use of the MTT assay, we performed signaling pathway analysis
by MetaCore using whole-gene expression data from 3 106
each of control, S1P, and estrogen-treated cells by Affymetrics
chip analysis. NAD(P)H-dependent cellular oxidoreductase
enzymes were not affected by S1P and estrogen treatment.
This indicates that difference of MTT assay data reflect the
number of viable cells rather than altered metabolism.
Alkaline phosphatase activity and alizarin red assay
Alkaline phosphatase activity was determined using a phospha-
tase substrate and a diazonium salt to substrate degradation as
blue color. Medium was removed; cells were washed with
phosphate-buffered saline and fixed with 60% acetone-citrate
for 30 seconds, then rinsed with deionized water. Substrate was
0.1mg/mL napthol AS-MX phosphate in buffer at pH 8. The
diazonium salt was fast violet, 0.6mg/mL. The reaction was
stopped by rinsing with water. Quantitative ALP activity was
quantified by densitometry analysis and normalized to cell
number to confirm the in situ labeling.
For alizarin red staining, cells were fixed in 70% ethanol and
stained with 1% alizarin red for 2 minutes. Cells were then
washed with distilled water and viewed under the light
microscope.
RNA and reverse transcription
Total RNA was prepared by phenol/guanosine isothicyanate
extraction (Trizol, Invitrogen, Carlsbad, CA, USA). RNAse inhibitor
(RNaseOUT, Invitrogen) was added for stability. RNA was
determined by absorbance at 260 nm. Reverse transcription
used 500 ng of total RNA, random hexamer primers, and
Moloney murine leukemia virus reverse transcriptase (Super-
script III; Invitrogen).
Real-time PCR
Quantitative polymerase chain reaction was as described(13)
using brilliant SYBRIII green (Stratagene, Agilent Technologies,
Santa Clara, CA, USA). Amixture with nucleotides and buffer was
used, adding 2.5mM Mg, 100 nM oligonucleotide primers, and
first-strand cDNA. After 10 minutes at 95°C, cycles of 15 seconds
at 95°C and 1 minute at 60°C were done. Messenger RNA
between samples was calculated using the comparative cycle
threshold (CT) method (DCT), using as control glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA. Sequences of
primers for PCR are shown in Table 1.
Genomewide expression screening
Osteoblast mRNA from 3 106 each of control cells or after
24-hour treatments with 1mM S1P, or 10 nM E2, was used to
make biotin-labeled cRNA and hybridized to Affymetrix (Santa
Clara, CA, USA) arrays as described.(14) These are DNA arrays on
glass, using the Hu 133.2 probe-set of 54675 oligo-DNAs, with
20 replicates per target. Segments of most genes, typically two
or more probes per gene, are included. Presence of transcripts
and differences between treatments were determined from the
signal and variation of each assay replicate, with statistical
confidence indicated. Analysis included determination of effects
on common metabolic pathways by MetaCore (St. Joseph, MI,
USA) comparing effects of S1P and estrogen treatment and
control against a library of 121 intracellular pathways. Analysis
excluded genes not expressed with p > 0.05. Differences with
p< 0.002 between conditions were included in analysis.
Cell lysates, Western blots, and antibodies
Cells were rinsed with cold PBS and lysed on ice in 150mMNaCl,
10mM EDTA, 50mM Tris, 1mM EDTA, 1mM orthovanadate,
15mM NaF, 1% Triton X-100, and 10% glycerol, pH 7.4, plus
phosphatase and proteinase inhibitors, for 10 minutes; lysates
were centrifuged to remove cell debris. Protein was determined
using the bicinchoninic acid (BCA) method. For Western
blotting, lysates were denatured in Laemmli sample buffer by
boiling, separated by SDS-polyacrylamide gel electrophoresis,
and transferred to polyvinylidene difluoride derivatized nylon.
Membranes were blocked in 5% BSA or milk in tris-buffered
saline-Tween 20, 1 hour, 20°C andwashed. Primary antibodywas
added overnight at 4°C. Rabbit monoclonal, anti-phospho-p44/
42 MAPK (ERK1/2), anti-p44/42 MAPK (ERK1/2), anti-phospho-
AKT, or anti-AKT (Cell Signaling, Danvers, MA, USA) were used
at 1:1000; rabbit polyclonal anti-S1PR1 and goat polyclonal
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anti-S1PR2 (Novus Biologicals, Littleton, CO, USA) were used at
1mg/mL; mouse monoclonal anti-actin (Sigma-Aldrich) was
used at 1:10000. After washing, secondary antibodies at 1:20,000
were added, 1 hour, 20°C (anti-rabbit IgG, anti-goat IgG, and
anti-mouse IgG, Jackson ImmunoResearch, West Grove, PA,
USA). Proteins were visualized by chemiluminescence (visual-
ized by enhanced chemiluminescence (Super SignalWest Femto
Maximum, Thermo Fisher Scientific, Waltham, MA, USA). Blots
were reprobed after membranes were stripped in Restore Plus
(Thermo Fisher Scientific).
Fluorescent assay for S1P production
Production of S1P was measured fluorometrically as de-
scribed.(15) Briefly, 1mg of mouse monoclonal SPHK1 antibody
was added to cell lysates incubated overnight at 4°C. Then
30mL of protein A/G agarose (Santa Cruz Biotechnology, Dallas,
TX, USA) was added at 4°C for 1 hour. Antibody precipitated
proteins were collected by centrifugation. Pellets were washed,
and 50mM HEPES, 30mM MgCl2, 0.1% Triton X-100, NaF, and
2mM ATP, pH 7.5, was added. Fifty microliters of this mixture
was incubated with 50mM NBD-sphingosine for 30 minutes at
room temperature; 100mL potassium phosphate, pH 8.5, was
added, followed by chloroform/methanol extraction (500mL,
2:1) with recovery of the NBD-S1P in the aqueous phase. The
aqueous layer was analyzed for NBD-S1P-fluorescence with
excitation at 485 nm and emission at 538 nm. A reaction
without SPHK served as blank. Activity is expressed as pmole/
minute/mg protein.
Statistics
Significance of paired of results was determined with Student’s
t test using Prism 5.0 (GraphPad, La Jolla, CA, USA). Data
represent at least two independent experiments (that is,
separate cell cultures) with two to four replicates from each
experiment. Differences were considered significant at p< 0.05.
Analysis of variances and the Newman-Keuls test were used for
multiple comparisons.



































Fig. 1. Effect of estrogen (E2) and sphingosine-1-phosphate (S1P) on human osteoblast cell growth at 24 hours. (A) Effect of estradiol, S1P, and an
S1PR agonist on osteoblast cell proliferation. At 24 hours, estradiol (10 nM) increased proliferation 20% relative to control. S1P (1mM) or
SEW2871 (1mM) induced cell growth but less than estradiol, 14% and 10%, respectively. Mean SEM, n¼ 6.p< 0.05, p< 0.01 versus control.
(B) Sphingosine kinase inhibitor (SKi) reduces the estradiol effect on proliferation. SKi alone did not affect proliferation (second bar); SKi with
estrogen reduced the effect of estrogen on cell proliferation by two-thirds. Mean SEM, n¼ 4. p< 0.01, ns (not significant), versus control;
p< 0.05 relative to estrogen only.
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Results
Estradiol or sphingosine-1-phosphate increase human
osteoblast proliferation at 24 hours
Active proliferating cells were evaluated using the MTT assay.
Regarding use of theMTT assay,weperformed signalingpathway
analysis by MetaCore using whole-gene expression data from
3 106 each of control, S1P, and estrogen-treated cells by
Affymetrics chip analysis. NAD(P)H-dependent cellular oxidore-
ductase enzymes were not affected by S1P and estrogen
treatment. This indicates that difference of MTT assay data reflect
the number of viable cells rather than altered metabolism.
In Fig. 1A, after exposure to 10 nM estradiol (E2) for 24 hours,
osteoblast proliferation increased 20% relative to the control
(p< 0.01). MTT also showed increases with sphingosine-1-
phosphate (S1P) (1mM), or with the sphingosine-1-phosphate
receptor-1 agonist SEW2871, by 10% to 14% (p< 0.05) at
24 hours. This is potentially important because of the receptor
specificity of this agonist.(16)
Further to investigate the involvement of sphingosine kinase
(SK) on the estradiol effect, hOB were treated with a nonspecific
sphingosine kinase inhibitor (SKi), with and without E2. SKi
inhibits both SPHK1 and SPHK2,(17) so this agent does not
differentiate which sphingosine kinases are active. However,
SPHK1 was expressed strongly in hOB; SPHK2 was not detected
in several assays. SKi alone did not affect the growth of
cells; however, it reduced the effect of E2 by about 80% in the
co-treatment (Fig. 1B), consistent with a role for sphingosine
kinase in the effect of estradiol on proliferation. Thus,
Fig. 2. Expression of S1P receptors and osteoblast differentiation-relatedmRNAs in human osteoblasts. (A) Analysis by real-time PCR of the expression of
S1P receptors 1, 2, and 3 (Ai) in correspondence with osteoblast-related mRNAs expression (Aii), including RUNX2, alkaline phosphatase, type I collagen,
and osterix in undifferentiated hOB and after 7, 14, and 21 days in differentiation medium. (B) Effect of 24-hour treatment with 10 nM estradiol (E2), or
200 nM S1P, on S1PR1-3 in undifferentiated hOB. Both E2 and S1P increase S1PR1mRNA expression, decrease S1PR2, and did not change S1PR3. (C) Both
S1PR1 and S1PR2 protein production by hOBwas increasedwith S1P treatment at 2weeks of differentiation. (D) In late differentiation (3weeks), effects of
S1P on receptor mRNAs were limited to minor effects on S1PR2. Relative to control, p< 0.05; p< 0.01.
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the sphingosine kinase pathway might be a mediator of a major
part of estradiol activity on proliferation.
Sphingosine-1-phosphate receptors are involved in hOB
proliferation and differentiation
PCR data for sphingosine-1-phosphate receptors are shown in
Fig. 2. During bone differentiation, S1PR2 was significantly
increased (p< 0.05) at 14 days of differentiation and then
decreased at 21 days (Fig. 2Ai) in correspondence with
osteoblast-related mRNA expression including RUNX2, alkaline
phosphatase, type I collagen, and osterix (Fig. 2Aii). S1PR1 and
S1PR3 decreased progressively at 7, 14, and 21 days of
differentiation (Fig. 2A). Expression of S1PR4 and S1PR5 in
hOB was negligible (not illustrated). Treatment with 10 nM E2 or
200 nM S1P, for 24 hours, decreased the mRNA expression for
S1PR2 but increased S1PR1 mRNA. There was no significant
effect on S1PR3 mRNA (Fig. 2B). At 2 weeks of hOB
differentiation, both S1PR1 and S1PR2 protein expression
measured by Western blot analysis showed a definite increase
with S1P treatment and a slight increase with estradiol (Fig. 2C).
At 3 weeks of osteoblast differentiation, the dose response of
S1P receptors was further evaluated; S1PR2 increased slightly
with 50 nM S1P, while the S1PR1 and S1PR3 were not changed
(Fig. 2D). These data, including the effect of the S1PR1 agonist
SEW2871 on proliferation, suggested that S1PR1 and S1PR2 are
involved in hOB differentiation and proliferation.
S1P and E2 effects on undifferentiated hOB are
mediated via activating the S1PR1/SPHK and MAP kinase
activity
We studied the dose-response effect of S1P on ER, S1PR1, and
SPHK1 mRNA expression in undifferentiated osteoblasts at
24 hours (Fig. 3A). S1P did not alter ERa mRNA (Fig. 3Ai), but it
upregulated ERb (Fig. 3Aii), S1PR1 (Fig. 3Aiii), and SPHK1
(Fig. 3Aiv) mRNA expression in a concentration-related manner.
At the same time point, 10 nM E2 upregulated SPHK1 mRNA
(Fig. 3Aiv) and protein expression. By Western blot, either 10 nM
E2 or 1mM S1PR1 agonist SEW2871 increased SPHK protein at
24 hours (Fig. 3C). These data are consistent with a mechanism
where E2-mediated proliferative effects, at least in part, occur
through S1PR1/SPHK activity.
To determine the effect of S1P and E2 on SPHK activity in
proliferating hOB, we measured S1P production by Fluorescent
assay. At 15 minutes, S1P at both concentrations, 200 nM and
1000 nM, increased SPHK activity (Fig. 3Bi); E2 at 10 nM had a
similar effect (Fig. 3Bii), confirming involvement of S1P and SPHK
in E2-mediated proliferative effects.
Previously, we reported that E2 promotes osteoblast
proliferation via activating the MAP kinase activity.(18) In this
study, we investigated the effect of S1P on the MAP kinase
activity in osteoblast precursors (h-MSC) and osteoblasts (hOB).
S1P-stimulated phospho-AKT and phospho-ERK at 15minutes in
h-MSC are shown on Fig. 3D. The concentration dependence of
Fig. 3. Short-term effect of S1P or E2 on osteoblast estrogen receptors, SPHK activity, andMAPK pathways. (A) Effect of 24-hour treatment with 1mMS1P
or 10 nM E2 on ER, S1PR, and SPHK1 mRNA expression. Note the concentration-dependent increase in ERb (ii), S1PR1 (iii), and SPHK1 (iv) mRNA
expression. Expression of ERa mRNA (i) was unaffected. Effect of estradiol, 10 nM, on mRNAs for SPHK1 at 24 hours (iv). Real-time PCR normalized to
GAPDH,mean range, n¼ 2 (independent experiments with 2 to 4 replicates). p< 0.05, p< 0.01 versus control. (B) Effect of (i) 200 nM or 1000 nM S1P
or (ii) 10 nM estradiol on sphingosine kinase activity. S1P stimulated the production of fluorescently labeled S1P, reflecting sphingosine kinase activity in
osteoblast lysates, after treatment for 15 minutes with unlabeled S1P, pmoles/min/mg protein. Effects of estradiol were similar; separate experiments
with separate controls. Mean SEM, n¼ 3 p< 0.01 versus control. (C) On Western blot, SPHK1 protein production was increased at 24 hours by 10 nM
estradiol, or the durable S1P receptor 1 agonist SEW2871, 1mM. (D) Effect of S1P (100 nM) on AKT and ERK phosphorylation in h-MSC in 5 and 15minutes.
S1P increased phospho-AKT and phospho-ERK at 15minutes relative to AKT and ERK or to b-actin. (E) S1P effect on AKT and ERK phosphorylation in hOB.
S1P increased phospho-AKT at 200 nM and 1000 nM S1P and slightly increase phospho-ERK at 1000 nM. (C–E) Quantification of two ECL blot images
normalized to equal total protein to eliminate artifacts of different loading or detection efficiency. p< 0.05; p< 0.01, ns (not significant).
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AKT and ERK phosphorylation at 10 minutes was studied in
osteoblasts (hOB) at 0, 200, and 1000 nM S1P (Fig. 3E), where
increased phosphorylation of AKT was found at 200 and 1000
nM S1P and a trend to increased ERK phosphorylation at
1000 nM S1P, which did not reach significance. Protein
expression and phosphorylation were quantified by densitome-
try analysis and normalized to the non-phosphorylated form or
to actin. These results suggest that osteoblasts’ response to the
S1P, as in other cells, at least in part, involve ERK and possibly
AKT phosphorylation.
E2 and S1P promote osteoblast differentiation
In bone differentiation medium, E2, 10 nM and S1P, 200 nM
enhanced differentiation, indicated by increasing ALP, after
3-week treatment. The expression ALP in the E2- and S1P-
treated group were higher than the control, as found in whole
9 cm(2) cultures with alkaline phosphatase staining (Fig. 4Ai).
ALP activity was quantified by densitometry analysis and
normalized to cell number to confirm the in situ labeling.
Either estradiol or S1P significantly (p< 0.01) increased ALP
activity normalized to cell number (Fig. 4B). The specificity of
ALP expression for the cell surfaces is shown at 20 (Fig. 4Aii).
Increased matrix is shown at 10 in phase (Fig. 4Aiii). The
increase of mineralization by S1P and E2 treatment was also
confirmed using alizarin red (Fig. 4Aiv). These results indicate
that both E2 and S1P promote osteoblast differentiation
in vitro.
Time course of S1P effects on osteoblast features, ERs,
and S1P-related genes
Further to explore the target that responds to S1P effect, we then
evaluated by real-time PCR the effect of S1P on the osteoblast-
relatedmRNAexpression, includingRUNX2,osterix (OSX), alkaline
phosphatase (ALP), and osteocalcin (OCN) for 7 to 21 days
(Fig. 5A). OSX and ALPmRNA expression by hOBwas significantly
increased with 200 nM S1P treatment at 7 days of differentiation.
There were decreases in RUNX2 (Fig. 5Ai) at 14 to 21 days, in
keeping with maturation of cells (that is, full differentiation),
whereas structural and mineralization-related genes, including
ALP (Fig. 5Aiii) and OCN (Fig. 5Aiv), were increased.
Because S1P showed the osteogenic effects comparable to
estradiol, ER mRNAs were also determined (Fig. 5B). In contrast
to effects of 200 nM S1P at 24 hours (Fig. 3Ai, ii), where only ERb
mRNA expression were increased, 7 days of differentiated hOB
treatment with 200 nM S1P significantly upregulated both ERa
and ERbmRNA. At 14 to 21 days, this effect was lost and both ERs
decreased, in keeping with cell maturation with reduced
response to growth and differentiation factors.
S1P targets, SPHK1, SGPP1, and ENPP1 mRNAs, were analyzed
at 7 days of hOB differentiation after treatment with 200 nM S1P
(Fig. 5C). SPHK1 mRNA expression was significantly increased at
7 and 14 days, and SGPP1was increased at 21 days. These results
are consistent with maintenance of, and in some cases
increased, S1P production and signaling during osteoblast
differentiation. The signal transduction pathways that control
Fig. 4. Estradiol (10 nM) or S1P (200 nM) promotes osteoblast differentiation. (A) (i) Alkaline phosphatase activity after treatment for 3 weeks is shown in
whole 9 cm2 cultures. (ii) Cells photographed after staining with ALP at 20 magnification without phase. (iii) At low power, 10, in phase, the dense
developing tissue and collagen are revealed. (iv) Cells photographed after staining with alizarin red at 20magnification. (B) ALP activity quantified by
densitometry analysis and normalized to cell number. Both estradiol and S1P increase ALP activity compared with the control. Results are mean SEM,
n¼ 4. p< 0.01 versus control.
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ENPP1 expression are not well known, although from our work
S1P does not upregulate ENPP1 mRNA in osteoblasts at 14 and
21 days of differentiation despite its association with osteoblast
phosphate production.
Inhibiting the sphingosine kinase (SKi) blocks the
effect of E2 on the expression of many, but not all,
osteoblast-related mRNAs
Fig. 6 shows representative estrogen-induced mRNAs in hOB,
after 7 days with or without 10 nM E2. In each case, RUNX2,
osterix (OSX), alkaline phosphatase (ALP), sphingosine kinase-1
(SPHK1), and the sphingosine-1-phosphate receptor-1 (S1PR1)
mRNAs are all induced significantly, 20% to 50%, by estradiol
relative to controls. Addition of 10mM SKi to controls in assays
for RUNX2 and ALP mRNAs did not affect their expression; the
other mRNAs were reduced significantly below the control.
Further, the combination of SKi and E2 reduced mRNA
expression relative to the control, except for sphingosine kinase
1 mRNA, which responded to estradiol with or without SKi.
The OPG/RANKL pathway, which is essential to balance of
bone formation and resorption, was evaluated for the effects of
S1P and E2. Although 10 nM E2 in differentiation medium for
2 weeks significantly reduced the ratio of RANKL to OPG, 200 nM
S1P did not change the ratio of RANKL to OPG (Fig. 6F). Addition
of 10mM SKi to the control hOB significantly reduced RANKL/
OPG. Further, the combination of SKi and E2 reduced the ratio of
RANKL to OPG mRNA expression relative to the control. These
results confirm that many, but not all, estrogen effects on hOB
differentiation are mediated, at least in part, via sphingosine
kinase activity.
Pathway analysis by whole-genome mRNA expression
We studied undifferentiated human osteoblasts under control
conditions or with addition of 10 nM estradiol or 200 nM S1P for
24 hours. Key pathway maps and changes in expression of
individual proteins are shown in the Supplemental Data. In brief,
osteoblast differentiation and cell adhesion pathways down-
stream of JAK kinases and signal transducer and activator of
transcription (Stat1 and Stat5) intermediates were found
(Supplemental Fig. S1). Additional cell adhesion and matrix
maturation proteins were linked to Rho/Rac receptors with
additional intracellular and cell surface targets, including actin
and integrins identified (Supplemental Fig. S2). In accord with
findings of S1P production, sphingosine kinase 1 activation
downstream of Map kinases was indicated (Supplemental
Fig. S3). An unexpected finding was strong activation by either
E2 or S1P of superoxide dismutase 1 or 2 expression
(Supplemental Fig. S4). Additional metabolic pathway links to
Rho and Rac signaling and intermediate kinases included
VEGF-A expression (Supplemental Fig. S5).
Discussion
Estradiol protects bone mass in a number of contexts and is
known to suppress production of RANKL, which induces
production of bone-degrading osteoclasts.(19) Estrogen signal-
ing has genomic and nongenomic components, including
estrogen signaling in bone.(13) In non-bone cells, including
breast cancer, an important nongenomic signal downstream of
estrogen is production of sphingosine-1-phosphate via SPHK1/
2.(6,20) Our work demonstrates, using assays of fluorescently
labeled S1P production, that estrogen or S1P, directly or
indirectly, induce S1P production (Fig. 3B); PCR for the
sphingosine kinase 1, SPHK1, andWestern blots were consistent.
The time courses of S1P action in osteoblasts and the levels of
S1P production in vivo are unknown; analyses of these are
important future goals. Although S1P production in response to
estrogen was not previously demonstrated in osteoblasts, it was
suggested in recent work that S1P induces the osteoblast-
related transcription factor RunX2 in osteoblasts under some
conditions(1) and promotes osteoblastic differentiation in
pluripotent cells (C3H10T1/2).(21) Our work on hOB did not
Fig. 5. Time-course effect of S1P on characteristic osteoblast, estrogen
receptors, and S1P-related mRNAs. All assays are real-time PCR in
duplicate, shown as mean range, and normalized in each case to
matched controls¼ 1.0; p< 0.05; p< 0.01. (A) Time-course effect of
200 nM S1P, with media changed every 3 days, on osteoblast-related
mRNAs. (B) Effect of long-term treatment with 200 nM S1P on estrogen
receptors (ERs). In contrast to effects at 24 hours (Fig. 2), where only ERb
increased, both ERa and ERb mRNAs increased after 1 week in 200 nM
S1P and dropped after 14 days, in keeping with cell maturation with
reduced response to growth and differentiation factors. (C) The response
to 200 nM S1P supplementation in media of S1P targets SPHK1, SGPP1,
and ENPP1mRNAs at 7, 14, and 21 day of hOB differentiation. The SPHK1,
SGPP1 showed variable effects, but each was increased at either 14 or
21 days. ENPP1 was downregulated in osteoblast differentiation.
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show similar RunX2 induction, although it is clear that cells
respond quite differently when studied under different
conditions.
Sphingosine-1-phosphate signaling is complex and it is often
difficult to separate functions of individual receptors. Overall,
S1PR1 mediates chemotaxis toward S1P via a Gi Rac, whereas
S1PR2 inhibits migration via G12/13 Rho, which inhibits Rac.
(22)
Further, S1PR1 stimulates proliferation via Gi-mediated path-
ways, including PI3K/Akt and Erk, whereas S1PR2 can inhibit
proliferation by Rho/Rho kinase-dependent Akt inhibition,
reviewed in Takuwa and colleagues.(22) More specifically for
MSC and bone, S1PR2 regulates MSC proliferation, migration,
and stability via increases in pluripotency factors that reduce
osteoblast or adipocyte differentiation.(23) S1PR1, S1PR2, and
S1PR3 are expressed by osteoblasts (Fig. 2). Importantly, S1PR1
expression in undifferentiated cells responds to S1P in a
concentration-dependent manner (Fig. 3Aiii). This is potentially
important because the S1PR1 agonist SEW2871(16) replicated
half of estrogen effects on osteoblast proliferation (Fig. 1A). In
other work, S1PR1 signaling modulates PDGF-induced motil-
ity.(24) Additional work on osteoblasts and osteoblast-like cells is
consistent with S1PR1 and S1PR2 regulation of osteoblast
maturation by kinase cascades,(1) although it is unclear the
relation of maintenance of undifferentiated MSC features to
osteoblast maturation.
Our work is consistent with involvement of Map kinases in S1P
regulation (Fig. 3 and Supplemental Figs. S1–5), although kinase
activation by S1PR3 was not strong. Studies in MSC maturation
also suggest that S1PR1/2 coordinate expression of kinases
including Akt,(25) pathways also supported by genomewide
expression data (Supplemental Fig. S2). In other cells including
breast cancer, S1P signals in part by MAP kinase activation,(26)
and in our work osteoblast response to S1P is consistent with
this. The induction ofMAP kinase leads to translocation of SPHK1
Fig. 6. Effects of estrogen are reversed in many, but not all, cases by inhibiting the sphingosine kinase. Representative estrogen-sensitive mRNAs in
human osteoblasts are shown. For RUNX2 (A), OSX (B), ALP (C), and S1PR1 (E), mRNA expressions were induced by 10 nM estradiol at 7 days. A 10-mM SKi
treatment reduced mRNA expression, and the combination of estradiol and SKi mRNA expression remained less than the control. The SPHK1 (D) mRNA
expression was decreased by the sphingosine kinase inhibitor SKi, but was induced by estradiol with or without SKi. (F) Estradiol and S1P have different
effects on the RANKL-OPG pathway. Data shown are for 7-day treatment. The untreated control is defined as 1.0. RANKL/OPGmRNA expression ratio was
decreased 60% to 80% by 5 nM estradiol treatment and further by the sphingosine kinase inhibitor (10mMSKi) treatment; the combination of SKi and
estradiol gave an intermediate result. On the other hand, RANKL/OPG was not reduced in 200 nM S1P. Media were changed at 3-day intervals. Duplicate
results range; p values are relative to control¼ 1.0 except when indicated by bars.
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from the cytosol to the plasma membrane, resulting in S1P
production.(27) It remains to be seen how related pathways are
affected in osteoblasts and comparisons with other cells. This
will determine the therapeutic potential for S1P activation and
inhibition in bone relative to other organs. Further, there is
evidence that S1P via S1PR3 is physiologically functional in
mouse marrow in commitment of stem cell precursors,(28)
arguing that the S1P system in bone needs to be further
analyzed.
There was overlap in effects of S1P and estrogen in human
osteoblasts in promoting short-term cell proliferation (Fig. 1).
That this overlap is due to functional biochemical linking is
suggested by partial replication of the effects of S1P by the
S1PR1 analog SEW2871 and that the S1P antagonist SKi opposed
the effects of estradiol. The effects of S1P and estradiol on
osteoblast maturation and bone formation also had strong
similarity (Fig. 4). Estradiol at 10 nMupregulated the sphingosine
kinase-1 at 24 hours, consistent with effects of estradiol on S1P
production (Fig. 3). It will be important, however, to determine
the half-life of S1P physiologically because human osteoblasts
also express the S1P lyase, which irreversibly inactivates S1P (not
illustrated). The expression and activity of sphingosine phos-
phatases are likely also to have important effects on S1P levels,
even though their effects are reversible. Our data show that
sphingosine-1-phosphate phosphatase 1, SGPP1, is expressed in
osteoblasts and regulated by S1P (Fig. 5C). Elements of the
pathway including the lyase and the SPHKs are potential
therapeutic targets in bone and other organs.(29) In osteoblast
differentiation, S1P reduced bone-regulating estrogen receptors
at late times, in keeping with cell maturation. Mature bone
cells (osteocytes) have reduced response to estrogen, losing ERa
and ERb.(30)
The concentrations of S1P used in cell biology represent the
range of typical and high-serum concentrations of 0.2 to 1mM;
further work will be needed to determine what part of this
range is relevant. In this regard, however, serum blood
concentrations of S1P are often 0.2mM in humans and
0.7mM in mice and including red blood cell S1P concentrations
may exceed 2mM, reviewed by Thuy and colleagues.(31) Serum
albumin facilitates release of S1P, without binding it.(31) In
bone, little is known about actual S1P concentrations, although
our data indicate that bone cells make significant amounts of
S1P (Fig. 3B).
Despite the clear overlap in S1P and estrogen signaling, some
genes respond to estradiol but not to S1P. A good example of
this is osteoprotegerin production relative to RANKL (Fig. 6).
Another example is the sphingosine kinase 1 mRNA, which is
upregulated by S1P at high concentrations or by 10 nM estradiol
(Fig. 3A, C), but where the estradiol effect is unchanged by
adding the sphingosine kinase inhibitor SKi (Fig. 6D). Determin-
ing tissue expression of S1P under varying conditions will be a
challenging target of further work and will be important to
evaluate the role of this new pathway in the regulation of bone
differentiation. Measurements of S1P in serum indicate that it
circulates at concentrations of 500 to 1000 nM,(32) albeit
significantly protein bound and in some circumstances released
by platelet activation. Carriers of S1P include albumin and
apolipoprotein M; in serum, S1P is important in vascular
homeostasis and immune cell response.(33,34) There are
precedents for osteoblast-derived S1P as potentially protecting
cancer proliferation,(35) but at present physiological levels of S1P
in bone and regulation of its production in vivo are not well
characterized.
We describe the function in bone cells of sphingosine-1-
phosphate production in response to estradiol via the SPHK,
with secondary effects via S1P and sphingosine-1-phosphate
receptors 1 and 2 that mediate, at least in part, estrogen effects
on bone. S1P production in osteoblasts is stimulated by estradiol
at high but physiological concentrations. There are many areas
of overlap between S1P-mediated and estradiol-mediated
effects on osteoblast maturation, although some differences
exist, including that estradiol, but not S1P, regulates production
of osteoprotegerin relative to RANKL. Differences in signaling
might be important in physiological response of bone to S1P
inhibitors or activators as potential modulators of bone
formation.
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